$GERN News
Last published 1w ago
- 1w agoGERNGeron Corporation to Present Data Highlighting Clinical and Biological Activity of RYTELO® (imetelstat) at ASH 2026GlobeNewswireFOSTER CITY, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused commercial stage biopharmaceutical company pursuing more meaningful moments for people living with blood
- 1w agoGERNGERON CORP - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoGERNQ3 2026 Geron Earnings Conference Call - GERON CORPEarnings Call TranscriptsHello, and welcome to the Geron Corporation Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To as
- 1w agoGERNQ3 2026 Geron Earnings Conference Call - GERON CORPEarnings Call TranscriptsHello, and welcome to the Geron Corporation Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To as
- 1w agoGERNGeron Corporation to Participate in the Stifel 2026 Healthcare ConferenceGlobeNewswireFOSTER CITY, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today
- 2w agoGERNGeron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory MyelofibrosisGlobeNewswireFOSTER CITY, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage hematology biopharmaceutical company, today announced the decision to discontinue the Phase 3 IMpactMF trial
- 3w agoGERNGeron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireFOSTER CITY, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today
- 3w agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today
- 4w agoGERNDid Geron Corporation Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireShareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket
- 1mo agoGERNGeron Corporation Announces Oral Presentations Highlighting Imetelstat at International Hematology Congresses in Europe and AsiaGlobeNewswirePresentations feature real-world experience and clinical evidence in lower-risk MDS, underscoring growing global scientific engagement with imetelstat FOSTER CITY, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Geron
- 1mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today
- 2mo agoGERNKuehn Law Encourages Investors of Geron Corporation to Contact Law FirmPR NewswireKuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Geron Corporation (NASDAQ: GERN)...
- 2mo agoGERNGeron to Present at Upcoming Investor ConferencesGlobeNewswireFOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today
- 2mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to
- 3mo agoGERNGeron Corporation Reports Second Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAchieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges
- 3mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase
- 3mo agoGERNGeron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireFOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 3mo agoENGNGERNRectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive ChairmanGlobeNewswireThe appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral
- 4mo agoGERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to
- 4mo agoGERNGeron Announces Appointment of Chinmaya Rath as Chief Business OfficerGlobeNewswireFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the
- 4mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase
- 5mo agoGERNGeron to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireFOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 5mo agoGERNBIOALCTXFATECell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative MarketsPR NewswireMarket News Updates News Commentary - Cell-based therapies are quickly becoming one of the most talked-about areas in healthcare as researchers move...
- 5mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an
- 6mo agoGERNFirst Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026GlobeNewswireInvestigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and
- 6mo agoGERNQ1 2026 Geron Earnings Conference Call - GERON CORPEarnings Call TranscriptsHello, and welcome to General Incorporation First Quarter 2026 Earnings Call. At this time, all participants are on listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask
- 6mo agoGERNGeron Corporation Reports First Quarter 2026 Financial Results and Recent Business HighlightsGlobeNewswireAchieved $51.8 million in RYTELO® (imetelstat) net product revenue in Q1 2026, an increase of 8% compared to the fourth quarter 2025 Reiterated 2026 RYTELO net product revenue and total operating expenses expected
- 6mo agoGERNGeron Plans to Present at Upcoming Investor ConferencesGlobeNewswireFOSTER CITY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 6mo agoGERNGeron Plans to Announce First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireFOSTER CITY, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 6mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective April 17, 2026, it granted stock options to purchase
- 7mo agoGERNGeron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to
- 7mo agoGERNApproval of Rytelo, Nda #217779 (Labeling)FDA Approved DrugsApproval Date: 04/14/2026; Drug Name: Rytelo, Nda #217779; Active Ingredients: IMETELSTAT SODIUM; Company: Geron; Submission Status: Approval; Submission Classification: Labeling; Application Number: 217779
- 7mo agoGERN25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE - GERON CORPEarnings Call TranscriptsGood morning, everyone, and thank you for joining us at the first day of the Needham Healthcare Conference. It is my pleasure to have with me today Harut Simerjan, the President and CEO of Geron, as well as Joseph E., th
- 7mo agoGERNGeron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswireFOSTER CITY, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the
- 7mo agoGERNGeron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswireFOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 7mo agoGERNGeron Announces Appointment of New Members to its Board of DirectorsGlobeNewswireFOSTER CITY, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the
- 8mo agoGERNNTLANAGEOCGNInvestors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B MilestonePR NewswireMarket News Updates News Commentary - The global anti-aging therapy market is gaining serious momentum as people live longer and actively look for...
- 8mo agoGERNGeron Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsGlobeNewswireAchieved $48 million and $184 million in RYTELO® (imetelstat) net product revenue in Q4 2025 and full year 2025, respectively Reported total operating expenses of $255 million for full year 2025, within the
- 8mo agoGERNGeron Plans to Present at Upcoming Investor ConferencesGlobeNewswireFOSTER CITY, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 8mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective February 17, 2026, it granted stock options to
- 9mo agoGERNGeron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026GlobeNewswireFOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
- 10mo agoGERNGeron Corporation Provides 2026 Financial GuidanceGlobeNewswire2026 RYTELO® (imetelstat) net product revenue expected in the range of $220 to $240 million 2026 total operating expenses expected in the range of $230 to $240 million Expected top-line growth and streamlined
- 10mo agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireFOSTER CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that, effective December 17, 2025, it granted stock options to
- 11mo agoGERNGeron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value CreationGlobeNewswireRestructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Geron
- 11mo agoGERNGeron Corporation Presents New Data at ASH 2025 Highlighting the Relationship Between Treatment-Emergent Cytopenias and Clinical Benefit of RYTELO® (Imetelstat) in Lower-Risk MDSGlobeNewswireOral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including hemoglobin increases and
- 11mo agoGTBPGERNKURASLS+1Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection PointsPR NewswireTriple-therapy immunotherapy approaches are demonstrating complete leukemia elimination in preclinical models by reprogramming how cancer cells die...
- 1y agoGERNGeron Corporation Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness WireAchieved $47.2 million in RYTELO® net product revenue in Q3 2025 Completed enrollment in Phase 3 IMpactMF clinical trial evaluating imetelstat in relapsed/refractory myelofibrosis Strengthened leadership team
- 1y agoGERNGeron Corporation to Present at Upcoming Investor ConferencesBusiness WireGeron Corporation (NASDAQ:GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled
- 1y agoGERNGeron Corporation Announces Five Presentations Selected for ASH 2025 Highlighting Clinical Activity of RYTELO® (imetelstat) in Myeloid Hematologic MalignanciesBusiness WireNew analysis from the Phase 3 IMerge clinical trial, accepted as an oral presentation, explores relationship between treatment-emergent cytopenias and clinical response in LR-MDS Additional poster presentations
- 1y agoGERNGeron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireGeron Corporation (NASDAQ:GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards on (i) October 17, 2025, covering an aggregate of 1,579,500 shares of its common stock,